Arrayit Corporation Logo

Arrayit Corporation (ARYC) leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure.  - Powerful Science for Life™

Corporate - Media & Press - Press Release

Arrayit featured on the cover of Genetic Engineering News.

Sunnyvale, CA, October 27, 2006 – On October 26th, Arrayit was featured on the cover of Genetic Engineering News, the first and most widely ready biotechnology publication in the world.  Introduced in 1981 by visionary Publisher Mary Ann Liebert, the scope of Genetic Engineering News includes basic and applied research, commercial science, regulatory issues, strategic alliances and corporate collaborations, clinical trials, corporate profiles, detailed interviews with academic, government and industry leaders, tutorials in drug discovery and diagnostics, and new products coverage that enables advances in life sciences research and development (R&D).  Genetic Engineering News literally represents a “one-stop shop” for the complete spectrum of issues in commercial science.

The cover article featuring TeleChem International’s technology “Microarrays Find their Way into the Clinic” was written by Neil McKenna.  The article focused on comparative genomic hybridization (CGH) and other applications of microarrays.  CGH is a technique that allows researchers to detect small alterations in the human genome, including insertions, deletions, duplications, and amplifications.  Alterations in the human genome are associated with a number of mental and physical defects including Down’s Syndrome, and various forms of cancer such as leukemia.  The combination of CGH and microarray technology is allowing researchers and clinicians to pinpoint these important genetic alterations with unprecedented speed and accuracy, and at a greatly reduced cost compared to traditional cytogenetic tests.

The Genetic Engineering News article included a detailed interview with company Co-Founder and Executive Vice President Todd Martinsky.  Mr. Martinsky shared his views on ArrayIt® brand microarray technology and CGH with the Genetic Engineering News staff.  “Choosing the DNA source and microarray type depends on the chromosomal changes and resolution that are to be detected by the assay,” Martinsky said.  “Our NanoPrint microarrayer, SpotLight scanner, surface chemistries, and other sample preparation products play a key role in any microarray experimental lifecycle.”  Mr. Martinsky also said “With oligonucleotides, it is possible to tile across the gene at specific lengths at a defined resolution,” emphasizing the fact that TeleChem International’s patented printing technology enables the manufacture of CGH microarrays containing oligonucleotides, complementary cDNAs, bacterial artificial chromosomes (BACs), and other types of DNA sequences.  The company co-founder was also quoted as saying: “If the assay is designed to discover new chromosomal disease associations, higher density microarrays are required,” also noting “These require more expensive microarray detection systems because of the required resolution.”     

The Director of Public Relations at the company, Paul K. Haje, provided the cover art for the article (see Fig. 1).  The company’s Public Relations Director Paul Haje was delighted by the coverage in Genetic Engineering News, saying “Mary Ann has done an amazing job with Genetic Engineering News over the years.  She has established and maintained the magazine as the world’s leading resource for biotechnology industry information, and we are absolutely delighted to be featured on the cover of the edition featuring clinical microarrays.” TeleChem International’s universally used and patented printing technology also appeared in an illustration describing approaches to CGH developed by CombiMatrix Molecular Diagnostics (see Fig. 2).

Genetic Engineering News
Figure 1. Shown is the cover of Genetic Engineering News from October 15, 2006.  Arrayit Corporation’s patented printing technology (U.S. 6,101,946) is featured in the caption on the right.

Arrayit patent
Figure 2. Shown is the bacterial artificial chromosome (BAC) comparative genomic hybridization (CGH) printing process at CombiMatrix Molecular Diagnostics.  TeleChem International, Inc’s ArrayIt® brand patented printing technology including microarray printing pins and a printhead are featured in the lower right portion of the illustration.

About Arrayit
TeleChem International is a privately owned high-tech company located in the heart of California’s Silicon Valley.  Our products and services are provided by three corporate divisions: ArrayIt® Life Sciences Division, Chemicals Division, and a Diagnostics Division. The ArrayIt® Life Sciences Division offers a complete microarray technology platform that empowers >10,000 laboratories to use microarrays for human genome exploration, basic research, drug discovery, and myriad life sciences applications.  Nearly every major research institution uses our patented microarray manufacturing technology (U.S. 6,101,946) and supporting products and services.  The Chemicals Division provides import and export services and government contract manufacturing in the area of industrial chemicals for plastics, fire control, water treatment, agriculture, industrial and institutional compounding, and green energy. The Diagnostics Division holds key patents in the United States (6,913,879), Singapore (94899), New Zealand (523560), and other countries for its revolutionary “multi-patient” genotyping technology, which allows as many as 100,000 patients to be tested on a single microarray. Arrayit Diagnostics enables genotyping and disease diagnostics by providing testing kits, services, and technology transfer opportunities for disease screening and testing organizations.

Media Contact
Arrayit Corporation
Telephone: 408-744-1331
Email: investorrelations@arrayit.com
Web: www.arrayit.com

 

 

Copyright 1993-2017 Arrayit Corporation. All rights reserved.